ethanol, opiates, benzodiazepines, antihistamines). In particular, butalbital, especially when combined with other sedatives (e.g. opioids), can cause life-threatening respiratory depression and death. Inhibitors of the hepatic enzyme CYP3A4 may also increase the risk, severity, and duration of side effects, many drugs inhibit this enzyme as do some foods such as grapefruit and the blood orange. Taking butalbital-based medications with some other drugs may also increase the side effects of the other medication. Dangers and risks
Butalbital can cause dependence or addiction. Mixing with alcohol, benzodiazepines, and other CNS-depressants increases the risk of intoxication, increases respiratory depression, and increases liver toxicity when in combination with paracetamol (acetaminophen). Use of butalbital and alcohol, benzodiazepines, and other CNS-depressants can contribute to coma, and in extreme cases, fatality. References
External links
Butalbital, Online Medical Dictionary
Butalbital and Acetaminophen (Systemic) (archive), MedicinePlus Drug Information
Controlled Substances in Schedule III, (archive), U.S. Drug Enforcement Administration
Chondrodysplasia punctata is a clinically and genetically diverse group of rare diseases, first described by Erich Conradi (1882–1968), that share the features of stippled epiphyses and skeletal changes. : 500 : 549

Types
Rhizomelic chondrodysplasia punctata  215100,  222765,  600121
X-linked recessive chondrodysplasia punctata  302950
Conradi–Hünermann syndrome (chondrodysplasia punctata 2, x-linked dominant)  302960
Autosomal dominant chondrodysplasia punctata  118650

See also
List of cutaneous conditions
List of radiographic findings associated with cutaneous conditions

References


== External links ==